## Pathogenesis

The current pandemic of COVID-19, caused by the SARS-CoV-2 virus, represents an acute global health crisis where symptoms can range from mild to severe or fatal [@url:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html], can affect a variety of organs and systems, and includes outcomes such as acute respiratory distress and acute lung injury, among other complications.
Viral pathogenesis is typically broken down into three major components: entry, replication, and spread [@isbn:0-9631172-1-1 {chap. 45}].
However, in order to get a more complete picture of pathogenesis, it is also necessary to examine how infection manifests clinically, identify systems-level interactions between the virus and the human body, and consider the possible effects of variation or evolutionary change on pathogenesis and virulence.
Though HCoV are not common and the SARS-CoV-2 virus appears to have emerged only recently, the rapid release of the genomic sequence of the virus in January 2020 provided early opportunities for comparative genomic analysis of the virus compared to its close phylogenetic relatives.
Because many mechanisms of pathogenicity are conserved among coronaviruses, this phylogenetic analysis provided an important basis for forming hypotheses about how the virus interacts with hosts.
Additionally, worldwide sequencing of viral samples has provided some preliminary insights into possible mechanisms of adaptation in the virus, and omics-based analysis of patient samples has elucidated some of the biological changes the virus induces in its human hosts.
In this way, both biomedicine and genomics are important pieces of the puzzle of SARS-CoV-2 presentation and pathogenesis. 

### Fundamental Viral Pathogenesis

As discussed above, the virus clusters with known coronaviruses (order *Nidovirales*, family *Coronaviridae*, subfamily *Orthocoronavirinae*).
Coronaviruses are large viruses that can be identified by their distinctive "crown-like" shape.
Their spherical virions are made from lipid envelopes ranging from 100 to 160 nanometers (nm) in which peplomers of 2-3 spike (S) glycoproteins are anchored, creating the crown [@isbn:978-0781760607; @doi:10/dvvg2h].
These spikes, which are critical to viral pathogenesis and host immune response, have been visualized using cryo-electron microscopy [@doi:10.1126/science.abb2507], trigger the human immune response, and are the target of many proposed therapeutic agents.
Phylogenetic analysis of the coronavirus clade indicates four major subclades, each corresponding to a genus: the alpha, beta, delta and gamma coronaviruses.
Among them, alpha and beta coronaviruses infect mammalian species, gamma coronaviruses infect avian species, and delta coronaviruses infect both mammalian and avian species [@doi:10.1146/annurev-virology-110615-042301].
Phylogenetic analysis of a PCR amplicon fragment from five patients along with the full genomic sequence revealed SARS-CoV-2 to be a novel betacoronavirus belonging to the B lineage, also known as sarbecovirus, which also includes the coronavirus SARS-CoV that causes SARS in humans [@doi:10/ggjs7j].
Because viral structure and mechanisms of pathogenicity are highly conserved within the order, this phylogenetic analysis provides a basis for forming hypotheses about how the virus interacts with hosts, including which tissues, organs, and systems would be most susceptible to SARS-CoV-2 infection.

#### Genomic Structure of Coronaviruses

Genome structure is highly conserved among coronaviruses, meaning that the relationship between the SARS-CoV-2 genome and its pathogenesis can be inferred from prior research in related viral species.
The genomes of viruses in the *Nidovirales* order share several fundamental characteristics.
They are non-segmented, which means the viral genome is contained in a single capsid, and are enveloped, which means that the genome and capsid are encased by a lipid bilayer.
Coronaviruses have large positive-sense RNA (ssRNA+) genomes ranging from 27 kilobases (Kb) to 32 Kb in length [@doi:10.1007/978-1-4939-2438-7_1; @doi:10/ggjr43].
The SARS-CoV-2 genome lies in the middle of this range at 29,903 bp [@doi:10/ggjr43].
Genome organization is highly conserved within the order [@doi:10.1007/978-1-4939-2438-7_1].
There are three major regions: one containing the replicase gene and one containing the genes encoding structural proteins [@doi:10.1007/978-1-4939-2438-7_1].
The replicase gene comprises about two-thirds of the genome of coronaviruses and consists of two open reading frames that are translated with ribosomal frameshifting [@doi:10.1007/978-1-4939-2438-7_1].
This polypeptide is then translated into 16 non-structural proteins (nsp1-16, except in Gammacoronaviruses, where nsp1 is absent) that form replication machinery used to synthesize viral RNA [@doi:10.1002/jmv.25681].
The remaining third of the genome encodes structural proteins, including the spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins.
Additional accessory genes are sometimes present between these two regions, depending on the species or strain.
<!-- TODO: Add a figure showing the structure of the genome.-->
Much attention has been focused on the S protein, which is a critical structure involved in cell entry.

#### Pathogenic Mechanisms of Coronaviruses

While, like most viruses, it is possible that SARS-CoV and therefore SARS-CoV-2 can enter cells through endocytosis, coronaviruses are able to target cells for entry through fusion with the plasma membrane [@doi:10.1038/cr.2008.15; @doi:10.1146/annurev-biochem-060208-104626].
This process is conserved among coronaviruses and is closely associated with the content of their genomes.
Cell entry proceeds in three steps: binding, cleavage, and fusion.
First, the viral spike protein binds to a host cell via a recognized receptor.
Coronaviruses can bind to a range of host receptors [@doi:10.3390/v4061011; @doi:10.1016/j.jmb.2020.04.009], with binding conserved only at the genus level [@doi:10.1146/annurev-virology-110615-042301].
Virus in the betacoronavirus genus, to which SARS-CoV-2 belongs, are known to bind to CEACAM1, Neu 5,9 Ac2, and Angiotensin-Converting Enzyme 2 (ACE2) [@doi:10.3390/v4061011].
SARS-CoV-2 has a high affinity for the human ACE2 receptor, which is expressed in the vascular epithelium, other epithelial cells, and cardiovascular and renal tissues [@doi:10.1007/s00134-020-05985-9; @doi:10.1007/978-0-387-33012-9_85].
The binding process is guided by the molecular structure of the spike protein, which is structured in three segments: an ectodomain, a transmembrane anchor, and an intracellular tail [@doi:10.1128/JVI.02615-14].
The ectodomain forms the crown-like structures on the viral membrane and contains two subdomains known as the S1 and S2 subunits [@doi:10.1038/nrmicro2090].
The S1 (N-terminal) domain forms the head of the crown and contains the receptor binding motif (RBM), and the S2 (C-terminal) domain forms the stalk that supports the head [@doi:10.1038/nrmicro2090].
The S1 subunit guides the binding of the virus to a host cell receptor, and the S2 subunit guides the fusion process [@doi:10.1128/JVI.02615-14].

After the binding of the S1 subunit to a receptor, the spike protein is often cleaved at the S1-S2 boundary by a host protease [@doi:10.1016/j.cell.2020.02.058; @doi:10/cf8chz; @doi:10.1016/j.antiviral.2020.104792].
Similar to SARS-CoV, SARS-CoV-2 exhibits redundancy in which host proteases can cleave the S protein [@doi:10.1016/j.cell.2020.02.052].
Specifically, both transmembrane protease serine protease-2 (TMPRSS2) and cathepsins B/L have been shown to mediate SARS-CoV-2 S protein proteolytic priming, and small molecule inhibition of these enzymes fully inhibited viral entry _in vitro_ [@doi:10.1016/j.cell.2020.02.052; @doi:10.1038/s41467-020-15562-9].
Proteolytic priming prepares the S protein for fusion [@doi:10/cf8chz; @doi:10.1016/j.antiviral.2020.104792].
The two subunits remain bound by van der Waals forces, with the S1 subunit stabilizing the S2 subunit during the membrane fusion process [@doi:10.1016/j.cell.2020.02.058].
Electron microscopy suggests that in some coronaviruses, including SARS-CoV and MERS-CoV, a six-helix bundle separates the two subunits in the postfusion conformation, and the unusual length of this bundle facilitates membrane fusion through the release of additional energy [@doi:10.1146/annurev-virology-110615-042301].
Cleavage at a second site within S2 by these same proteases activates _S_ for fusion by inducing conformational changes [@doi:10.1016/j.cell.2020.02.058].
The viral membrane can then fuse with the endosomal membrane to release the viral genome into the host cytoplasm.
Once the virus enters a host cell, the replicase gene is translated and assembled into the viral replicase complex.
This complex then synthesizes the double-stranded RNA (dsRNA) genome from the genomic ssRNA(+).
The dsRNA genome is transcribed and replicated to create viral mRNAs and new ssRNA(+) genomes [@doi:10.1007/978-1-4939-2438-7_1; @url:https://viralzone.expasy.org/30?outline=all_by_species].
From there, the virus can spread in other cells.
Thus, the genome of SARS-CoV-2 is likely to provide insight into the pathogenic behavior of the virus.

#### Immune Evasion Strategies

Research in other coronaviruses that affect humans provides some indication of how SARS-CoV-2 infection proceeds in spite of the human immune response.
By infecting the epithelium, viruses such as SARS-CoV are known to bypass the physical barriers such as skin and mucus that comprise the immune systems' first line of defense [@doi:10.1038/mi.2015.127].
Once the virus infiltrates host cells, it is adept at evading detection.
CD163+ and CD68+ macrophage cells especially are crucial for the establishment of SARS-CoV in the body [@doi:10.1038/mi.2015.127].
These cells most likely serve as viral reservoirs that help shield SARS-CoV from the innate immune response.
According to a study on the viral dissemination of SARS-CoV in Chinese macaques, viral RNA could be detected in some monocytes throughout the process of differentiation into dendritic cells [@doi:10.1038/mi.2015.127].
This lack of active viral replication allows SARS-CoV to escape innate immunity because reduced levels of detectable viral RNA allow the virus to avoid both natural killer (NK) cells and Toll-like receptors [@doi:10.1038/mi.2015.127].
Even during replication, SARS-CoV is able to mask its dsRNA from detection by the immune system.
Although dsRNA is a pathogen-associated molecular pattern (PAMP) that would typically initiate a response from the innate immune system [@doi:10.3389/fimmu.2018.00829], _in vitro_ analysis of nidoviruses including SARS-CoV suggests that these viruses can induce the development of double-membrane vesicles that protect the dsRNA signature from being detected by the host immune system [@doi:10.1128/jvi.02501-05].
This protective envelope can therefore insulate these coronaviruses from the innate immune response's detection mechanism [@doi:10.1016/j.jpha.2020.03.001].

HCoV are also known to interfere with the host immune response, rather than just evade it.
For example, the virulence of SARS-CoV is increased by nonstructural protein 1 (Nsp1), which can suppress host gene expression.
Nsp1 accomplishes this by stalling mRNA translation and inducing endonucleolytic cleavage and mRNA degradation [@doi:10.1126/science.abc8665].
SARS-CoV also evades the immune response by interfering with type I IFN induction signaling, which is a mechanism that leads to cellular resistance to viral infections.
SARS-CoV employs methods such as ubiquitination and degradation of RNA sensor adaptor molecules MAVS and TRAF3/6 [@doi:10.12932/AP-200220-0772].
Also, MERS-CoV downregulates antigen presentation via MHC class I and MHC class II, which leads to a reduction in T cell activation [@doi:10.12932/AP-200220-0772].
These evasion mechanisms, in turn, can lead to systemic infection.
Coronaviruses such as SARS-CoV are also able to evade the humoral immune response through other mechanisms, such as inhibiting certain cytokine pathways or down-regulating antigen presentation by the cells [@doi:10.1128/jvi.02501-05].

#### Host Cell Susceptibility

ACE2 and TMPRSS2 have been identified as a primary receptor and a critical protease, respectively, facilitating the entry of SARS-CoV/CoV-2 into a target cell [@doi:10.1038/nature02145; @doi:10.1126/science.abb2507; @doi:10.1128/JVI.01542-10; @doi:10.1016/j.cell.2020.02.052; @doi:10.1128/JVI.02232-10].
This finding has led to a hypothesized role for ACE2 and TMPRSS2 expression in determining which cells, tissues, and organs are most likely to be infected by SARS-CoV-2.
The ACE2 receptor is expressed in numerous organs, such as the heart, kidney, and intestine, but is most prominently expressed in alveolar epithelial cells; this pattern of expression is expected to contribute to the virus' association with lung pathology [@doi:10.1101/2020.02.24.963348; @doi:10.1007/s00134-020-05985-9].
Clinical investigations of COVID-19 patients have detected SARS-CoV-2 transcripts in bronchoalveolar lavage fluid (93% of specimens), sputum (72%), nasal swabs (63%), fibrobronchoscopy brush biopsies (46%), pharyngeal swabs (32%), feces (29%) and blood (1%) [@doi:10.1001/jama.2020.3786].
Two studies reported that SARS-CoV-2 could not be detected in the urine specimens [@doi:10.1001/jama.2020.3786; @doi:10.1001/jama.2020.3204]; however, a third study identified four urine samples (out of 58) that were positive for SARS-CoV-2 nucleic acids [@doi:10.1097/CM9.0000000000000774].
Although respiratory failure remains the leading cause of death for COVID-19 patients [@doi:10.1111/his.14134], SARS-CoV-2 infection can damage many other organ systems including the heart [@doi:10.1001/jamacardio.2020.0950], kidney [@doi:10.1038/s41585-020-0319-7; @doi:10.1186/s13054-020-02872-z], liver [@doi:10/ggpx6s], and gastrointestinal tract [@doi:10.1053/j.gastro.2020.02.055; @doi:10.1111/1751-2980.12851].
As it becomes clearer that SARS-CoV-2 infection can damage diverse organs, the scientific community is pursuing multiple avenues of investigation in order to build a consensus about how the virus affects the human body.

### Clinical Presentation of COVID-19

Reports have described diverse symptom profiles associated with COVID-19.
A large study from Wuhan, China suggests fever and cough as the two most common symptoms at hospital admission [@doi:10.1056/NEJMoa2002032], and another early retrospective study in China described the clinical presentations of patients infected with SARS-CoV-2 as including lower respiratory tract infection with fever, dry cough, and dyspnea [@doi:10/ggnxb3].
This study [@doi:10/ggnxb3] noted that upper respiratory tract symptoms were less common, which suggested that the virus was targeting cells located in the lower respiratory tract.
A later study reported radiographic findings such as ground-glass opacity and bilateral patchy shadowing in the lungs of many hospitalized patients, and most COVID-19 patients had lymphocytopenia, meaning they had low levels of lymphocytes (a type of white blood cell) [@doi:10.1056/NEJMoa2002032].
However, data from the New York City region [@doi:10.1001/jama.2020.6775; @doi:10.1056/NEJMc2010419] showed variable rates of fever as a presenting symptom, suggesting that symptoms may not be consistent across samples.
These differences persist when comparing both between institutions in similar locations and between different regions experiencing COVID-19 outbreaks, leading to conflicting reports of the frequency of fever as a presenting symptom for patients upon hospital admission.
For example, even within New York City, one study [@doi:10.1001/jama.2020.6775] identified low oxygen saturation (<90% without the use of supplemental oxygen or ventilation support) in a significant percentage of patients on presentation, while another study [@doi:10.1056/NEJMc2010419] reported cough, fever, and dyspnea as the most common presenting symptoms.
Patients may also experience loss of smell, myalgias (muscle aches), fatigue, or headache.
Radiographic findings such as ground-glass opacity and bilateral patchy shadowing in the lungs of many hospitalized patients have also been reported, and most COVID-19 patients had lymphocytopenia, meaning they had low levels of lymphocytes (a type of white blood cell) [@doi:10.1056/NEJMoa2002032].
The variability of both which symptoms present and their severity makes it difficult for public health agencies to provide clear recommendations for citizens regarding what symptoms indicate SARS-CoV-2 infection and should prompt isolation.
For example, evidence suggests that gastrointestinal symptoms presentation does occur [@doi:10.15585/mmwr.mm6928a2], and the CDC has updated its list of symptoms suggestive of COVID-19 to include nausea and vomiting, as well congestion and runny nose [@url:https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html].
A recent preprint using data from an app-based survey of 500,000 individuals in the US found that among those tested for SARS-CoV-2, a loss of taste or smell, fever, and a cough were significant predictors of a positive test result [@doi:10.1101/2020.06.09.20126813].
It is important to note that in this study, the predictive value of symptoms may be underestimated if they are not specific to COVID-19 because the outcome measured was a positive, as opposed to a negative, COVID-19 test result.
At the time the surveys were conducted, due to limits in US testing infrastructure, respondents typically needed to have some symptoms known to be specific to COVID-19 in order to qualify for testing in the first place.
Widespread testing of asymptomatic individuals may therefore provide additional insight into the range of symptoms associated with COVID-19.

COVID-19 can affect diverse body systems in addition to causing respiratory problems [@doi:10.1038/s41591-020-0968-3].
For example, COVID-19 can lead to acute kidney injury, especially in patients with severe respiratory symptoms or certain preexisting conditions [@doi:10.1016/j.kint.2020.05.006].
It can also cause neurological complications [@doi:10.1016/j.bbi.2020.03.031; @doi:10/d259], potentially including stroke, seizures or meningitis [@doi:10.1002/jmv.26000; @doi:10.1002/ana.25807].
COVID-19 has also been associated with an increased incidence of large vessel stroke, particularly in patients under the age of 40 [@doi:10.1056/NEJMc2009787], and other thrombotic events including pulmonary embolism and deep vein thrombosis [@doi:10.1016/j.thromres.2020.04.013].
The mechanism behind these complications has been suggested to be related to coagulopathy with reports of antiphospholipid antibodies present [@doi:10.1056/NEJMc2007575] and elevated levels of d-dimer and fibrinogen degradation products (FDP) elevated in deceased patients [@doi:10.1111/jth.14768].
Other viral infections have been associated with coagulation defects; notably SARS was also found to lead to disseminated intravascular coagulation (DIC) and was associated with both pulmonary embolism and deep vein thrombosis [@doi:10.1002/jmv.23354].
A wide range of viral infections can affect the coagulation cascade.
The mechanism behind these insults has been suggested to be related to inflammation-induced increases in the von Willebrand factor (VWF) clotting protein, leading to a pro-coagulative state [@doi:10.1002/jmv.23354].
Abnormal clotting (thromboinflammation or coagulopathy) has been increasingly discussed recently as a possible key mechanism in many cases of severe COVID-19, and may be associated with the high d-dimer levels often observed in severe cases [@doi:10/ggvd74; @doi:10.1186/s13054-020-03060-9; @doi:10.1007/s11239-020-02134-3].
This excessive clotting in lung capillaries has been suggested to be related to a dysregulated activation of the complement system, part of the innate immune system [@doi:10.1172/jci.insight.140711; @doi:10.1172/JCI140183].

#### Cytokine Storm

Symptoms of a disease can be caused by a pathogen, but they can also be caused by the immune system's reaction to the pathogen.
Although the immune system response is typically effective in defending a host against infection, a dysregulated response can cause significant damage to the host [@isbn:9780815332183; @isbn:9780071283663; @doi:10.1016/j.chom.2020.05.009].
The inflammatory response has received particular attention for its role in both a healthy response to infection and a pathogenic one.
Inflammation is one of the most visible components of the immune response, as it is responsible for hallmarks of injury such as pain, swelling, etc. [@doi:10.18632/oncotarget.23208].
In response to injury or to signaling by PRRs, the immune system stimulates leukocytes that travel to the site of the threat, where they then produce cytokines [@doi:10.18632/oncotarget.23208].
Cytokines are a diverse group of small proteins that play an important role in intercellular signalling [@doi:10.1128/MMBR.05015-11].
This category includes interleukins, which are produced by and regulate the development of leukocytes, interferons, which play an antiviral and antiproliferative role in responding to viral threat, and tumor necrosis factors, which activate cytotoxic T-lymphocytes [@doi:10.1128/MMBR.05015-11; @doi:10.1097/AIA.0b013e318034194e].
Cytokines can be both pro- and anti-inflammatory, which means they can either signal for additional cytokine activity or inhibit the production of additional cytokines [@doi:10.1097/AIA.0b013e318034194e].
Dysregulation therefore refers to excessive pro-inflammatory cytokine activity unchecked by the anti-inflammatory counterparts, which can therefore cause a cascade of the inflammatory response [@doi:10.1159/000087104].

##### Cytokines and Pulmonary Infection

Cytokines have been investigated for their role in the immune response to lung infections long before the COVID-19 pandemic.
Dysregulation of the inflammatory response, including elevated levels of pro-inflammatory cytokines, is found in patients with ARDS [@doi:10.1159/000087104].
One study of patients with and at risk for ARDS (specifically, intubation) found that shortly after the onset of ARDS, anti-inflammatory cytokine concentration in BALF increased relative to the concentration of pro-inflammatory cytokines [@doi:10.1164/ajrccm.164.10.2104013].
Patients with severe ARDS were excluded from this study, and their results suggest that an increase in pro-inflammatory cytokines such as interleukin-6 (IL-6) may signal the onset of ARDS, but recovery depends on an increased anti-inflammatory response [@doi:10.1164/ajrccm.164.10.2104013].
The acute phase response to the infection may cause damage to the capillary endothelium, allowing leaks that disrupt the balance between cytokines and their regulators [@doi:10.1164/ajrccm.164.10.2104013].
Hyperactivity of the pro-inflammatory response due to lung infection is commonly associated with acute lung injury and more rarely with its more severe manifestation, ARDS [@doi:10.1128/MMBR.05015-11].
The heightened inflammatory response in the lungs can also serve as a source for systemic inflammation, or sepsis [@doi:10.1128/MMBR.05015-11].
The shift from local to systemic inflammation is a phenomenon known as a cytokine storm [@doi:10.1128/MMBR.05015-11].
Sepsis is a known possible complication of pneumonia, and in an analysis of over 1400 US pneumonia patients, interleukin-6 (IL-6), tumor necrosis factor (TNF), and IL-1&beta; were found to be elevated at intake in patients who developed severe sepsis and/or ultimately deceased [@doi:10.1001/archinte.167.15.1655].
IL-6 and TNF are pro-inflammatory cytokines, while IL-1&beta; is 

##### The Role of Cytokines in COVID-19

The inflammatory response is likely to be an important driver of COVID-19 outcomes.
In addition to the known role of cytokines in ARDS and lung infection more broadly, deceased SARS-CoV patients were found to have intermediate levels of IL-6, IL-1ùõΩ, and TNF-Œ± expressed in a number of ACE2-expressing cell types sampled from the lung and bronchial tissues during autopsy [@doi:10.1002/path.2067].
The introduction of the S-protein from SARS-CoV to mouse macrophages was found to increase production of IL-6 and TNF-Œ± [@doi:10.1016/j.virusres.2007.02.007].
One severe example includes reports of cytokine storm-like responses in patients with particularly severe infections, in which the overproduction of inflammatory cytokines leads to systemic inflammation and potentially multi-organ failure, which may very well accelerate the spread of virus in the host [@doi:10.1101/2020.02.24.963348; @doi:10/ggnzmc].
In general, the interferons (IFNs) activate intracellular antimicrobial programs and are the major first line of defense against viruses [@doi:10.1016/j.chom.2020.05.008].
I
For example, interferon-mediated innate antiviral responses initiated by the virus-infected cells can have inflammatory and other systemic effects that are severe [@doi:10.1016/j.chom.2020.05.008].
Interleukin 6 (IL-6) is a pleiotropic cyotkine that plays a role in both the inflammatory and anti-inflammatory responses and is associated both with a healthy response to a viral threat as well as a pathological one [@doi:10.3389/fmicb.2019.01057].
IL-6 promotes the differentiation of activated B cells into immunoglobulin-producing plasma cells [@pmid:9052836], thereby playing an important role in the immune system's ability to adapt to a viral threat, and it also induces the differentiation of na√Øve CD4+ T cells into effector T-cell subsets [@doi:10.1158/2326-6066.CIR-14-0022].
In this way, interleukins like IL-6 are integral to both the pro- and anti-inflammatory responses.

IFNs are a type of cytokines along with chemokines, interleukins (IL), lymphokines and tumor necrosis factor (TNF).
Cytokines can be classified based on the nature of the immune response or based on their specific roles, as reviewed by [@doi:10.1016/j.bbamcr.2014.05.014]).
[@doi:10.1016/j.immuni.2020.06.017] describe the concept of the cytokine storm in detail, although [@doi:10.1001/jamainternmed.2020.3313] claim that the widespread use of the term can be misleading.

<!-- Suggestion: define distinction between Cytokine Release Syndrome and Cytokine Storm Syndrome-->

#### Pediatric Presentation

The presentation of COVID-19 infection can vary greatly among pediatric patients and in some cases manifests in distinct ways from COVID-19 in adults.
A review examined symptoms reported in 17 studies of children infected with COVID-19 during the early months of the COVID-19 epidemic in China and one study from Singapore [@doi:10.1001/jamapediatrics.2020.1467].
Of the more than a thousand cases described, the most commonly reports were for mild symptoms such as fever, dry cough, fatigue, nasal congestion and/or runny nose, while three children were reported to be asymptomatic.
Severe lower respiratory infection was described in only one of the pediatric cases reviewed.
Gastrointestinal symptoms such as vomiting or diarrhea were occasionally reported.
Radiologic findings were not always reported in the case studies reviewed, but when they were mentioned they included bronchial thickening, ground-glass opacities, and/or inflammatory lesions [@doi:10.1001/jamapediatrics.2020.1467].
Neurological symptoms have also been reported [@doi:10.1001/jamaneurol.2020.2687].

These analyses indicate that most pediatric cases of COVID-19 are not severe.
However, serious complications and, in rare cases, deaths have occurred [@doi:10.1016/j.eclinm.2020.100433].
Of particular interest, children have occasionally experienced a serious inflammatory syndrome, multisystem inflammatory syndrome in children (MIS-C), following COVID-19 infection.
This syndrome is similar in some respects to Kawasaki disease or to Kawasaki disease shock syndrome [@doi:10.1093/jpids/piaa069; @doi:10.1001/jama.2020.10369; @doi:10.1016/j.ajem.2020.05.117] and is thought to be a distinct clinical manifestation of SARS-CoV-2 due to its distinct cytokine profile and the presence of burr cells in peripheral blood smears [@doi:10.1172/JCI140970].
MIS-C has been associated with heart failure in some cases [@doi:10.1161/CIRCULATIONAHA.120.048360].
One case study [@doi:10/gg4sd6] described an adult who appeared to show symptoms similar to MIS-C after exposure to COVID-19, but cautioned against broad conclusions; a second possible adult case has also been reported [@doi:10.1016/j.ajem.2020.06.053].
The presentation of SARS-CoV-2 infection is therefore likely to be largely distinct between adult and pediatric populations.

### Systems-Level Effects

Systems biology provides a cross-disciplinary analytical paradigm through which the host response to an infection can be analyzed.
This field integrates the "omics" (genomics, transcriptomics, proteomics, metabolomics, etc.) with bioinformatics and other computational strategies.
These cutting-edge research approaches hold enormous potential for the study of the complexity of biological systems and human diseases [@doi:10.1016/j.gpb.2012.08.004].
Over the last decade, systems biology approaches have been used widely to study the pathogenesis of diverse types of life-threatening acute and chronic infectious diseases [@doi:10.1038/s41576-020-0212-5].
Omics-based studies have also provided meaningful information regarding host immune responses and surrogate protein markers in several viral, bacterial and protozoan infections [@doi:10.1002/prca.201300074].
Though the complex pathogenesis and clinical manifestations of SARS-CoV-2 infection are not yet fully understood, ‚Äúomics‚Äù technologies offer the opportunity to discovery-drive analysis of biological changes associated with SARS-CoV-2 infection.
For example, previous studies suggest that infection by coronaviruses such as SARS-CoV and MERS-CoV and other viruses is associated with the upregulation of ACE2.
In several preliminary assays and an analysis of previous microarray data, ACE2 expression was reported to be significantly upregulated following infection of human embryonic kidney cells and human airway epithelial cells [@doi:10.1101/2020.02.24.963348].
They also reported that direct stimulation with inflammatory cytokines such as type I interferons (e.g., IFN&beta;) resulted in the upregulation of ACE2 in human bronchial epithelial cells, with treated groups showing four-fold higher ACE2 expression than control groups at 18 hours post-treatment [@doi:10.1101/2020.02.24.963348].
G
Whether SARS-CoV-2 facilitates the positive regulation of its own transmission between host cells is still unclear, the host immune response itself likely plays a key role in mediating infection-associated pathologies.
A systems-biology approach allows for analyses such as these to identify possible phenotypic and endophenotypic responses to SARS-CoV-2 infection and to develop new hypotheses about how pathogenesis proceeds.

#### Transcriptomics

In addition to the study described above, two other studies have profiled expression following SARS-CoV-2 infection using human cell lines.
The first study [@doi:10.1016/j.cell.2020.04.026] compared transcriptional responses to SARS-CoV-2 and to other respiratory viruses, including MERS-CoV, SARS-CoV, human parainfluenza virus 3 (HPIV3), respiratory syncytial virus (RSV), and influenza A virus (IAV).
<!-- TODO: What does modulating moi tell us? -->
They analyzed the responses of three human cell lines: A549 (adenocarcinomic human alveolar basal epithelial cells), Calu-3 (human airway epithelial cells derived from human bronchial submucosal glands), and MRC-5 (human fetal lung fibroblast cells).
As the viral receptor ACE2 has low expression in A549 cells, they supplemented the A549 cells with adenovirus (AdV)-based vectors expressing either mCherry (a fluorescent protein used as a control) or ACE2 (A549-ACE2).
All infections were performed at a high MOI (2‚Äì5), with the exception of A549-ACE2 cells, which were infected with SARS-CoV-2 at both low (0.2) and high (2) MOI.
Poly(A) bulk RNA sequencing (RNA-seq) of host cells was performed at 24 hours post-infection (hpi) of all the viruses except for IAV, which was formed at 9-12 hours.
The authors also measured host transcriptional responses to SARS-CoV-2 in primary normal human bronchial epithelial cells (HBEC or NHBE cells), nasal washes from an animal model (ferret), and lung samples from two COVID-19 patients.
Additionally, they measured transcriptional responses to IAV in the NHBE cells and the nasal washes of ferrets.
Differential expression (DE) analysis was then carried out to compare infected cells with control cells that underwent only a mock treatment.
n the hosts where SARS-CoV-2 was able to replicate efficiently, DE analysis revealed that the transcriptional response was significantly different from the response to all of the other viruses tested.
A unique proinflammatory cytokine signature associated with SARS-CoV-2 was present under both high- and low-MOI conditions, with the cytokines IL-6 and IL1RA uniquely elevated in response to SARS-CoV-2.
A549-ACE2 cells showed significant IFN-I or IFN-III expression only at high MOI.
This finding suggests that IFN induction is MOI dependent.
Similarly, in cells from the NHBE line, ferrets, and COVID-19 patients, chemokine signaling was significantly enriched, but there was no significant induction of IFN-I or IFN-III.
Together, these results suggest that in contrast to common respiratory viruses, SARS-CoV-2 induces a limited antiviral state with low IFN-I or IFN-III expression and a moderate IFN-stimulated genes (ISG) response.
However, the low IFN induction in ACE2-expressing A549 cells could be overcome by using a 10-fold increase in SARS-CoV-2 (MOI, 2), suggesting a SARS-CoV-2 antagonist that is rendered ineffective under high-MOI conditions [@doi:10.1016/j.cell.2020.04.026].
This hypothesis was further supported by a recent study [@doi:10.1101/2020.05.11.088179] that showed that the SARS-CoV-2 _ORF3b_ gene suppresses IFNB1 promoter activity (IFN-I induction) more efficiently than the SARS-CoV_ORF3b_ gene.
<!--TO DO: The main finding of this study is therefore that... (tie back into broader questions related to pathogenesis)--> 

A second study [@doi:10.1101/2020.05.05.079194] analyzed cells' transcriptional response to SARS-CoV-2 and SARS-CoV over time.
They characterized the response of three human cell lines at 4 to 36 hpi at an MOI of 0.3: H1299 (human non-small cell lung carcinoma cell line), Calu-3, and Caco-2 (human epithelial colorectal adenocarcinoma cell line).
Using poly(A) bulk RNA-seq, the authors found negligible susceptibility of H1299 cells (< 0.08 viral read percentage of total reads) compared to Caco-2 and Calu-3 cells (>10% of viral reads).
This finding suggests that cell type is likely to play an important role in host viability.
Based on visual inspection (microscopy images) and transcriptional profiling, the authors also showed distinct responses associated with different hosts following infection.
In contrast to Caco-2, Calu-3 cells infected with SARS-CoV-2 showed signs of impaired growth and cell death at 24 hpi, as well as moderate IFN induction with a strong up-regulation of ISGs. <!--TO DO: define ISG-->
Interestingly, the response is similar to SARS-CoV-2 infected Calu-3 cells at ~7-fold higher MOI performed by Blanco-Melo et al., suggesting that IFN induction is not MOI dependent in Calu-3 cells, in contrast to reports using A549-ACE2 cells.
The discrepancy could be explained by the observations that Calu-3 cells are highly susceptible to SARS-CoV-2 with rapid viral replication [@doi:10.1038/s41467-020-15562-9], whereas A549 cells are incompatible with SARS-CoV-2 infection [@doi:10.1101/2020.03.02.972935].
We performed a correlation analysis of the host expression response (RNA fold change compared to the mock infection) using the publicly available analyzed data from Blanco-Melo et al. and Wyler et al. (Figure {@fig:cell-lines-moi}B) [@doi:10.1016/j.cell.2020.04.026; @doi:10.1101/2020.05.05.079194].
In general, we found high correlations among the same host irrespective of the study and the virus infected, suggesting that the response is host-specific.
For instance, Calu-3 cells infected with SARS-CoV by Wyler et al. and Calu-3 cells infected with SARS-CoV-2 by Blanco-Melo et al. had a Pearson's correlation coefficient of 0.8 (Figure {@fig:cell-lines-moi}B).
Moreover, samples from COVID-19 patients had the lowest correlations among all the cells used, with the highest value being 0.29.
This discrepancy suggests that the _in vitro_ models used may not necessarily imitate the human response, underscoring the importance of follow-up in additional models.

#### Proteomics

Even though no comprehensive proteomic analysis of the pathogen or of patients suffering from its infection has yet been reported, one forthcoming study has demonstrated SARS-CoV-2 infected host cell proteomics using human Caco‚Äì2 cells as an infection model [@doi:10.1038/s41586-020-2332-7].
The authors observed SARS-CoV-2 induced alterations in multiple vital physiological pathways, including translation, splicing, carbon metabolism and nucleic acid metabolism in the host cells.
There is a high level of sequence homology between SARS-CoV-2 and SARS-CoV, and it has been hypothesized that sera from convalescent SARS-CoV patients might show some efficacy to cross-neutralize SARS-CoV-2-S-driven entry [@doi:10.1016/j.cell.2020.02.052].
However, despite the high level of sequence homology, certain protein structures might be immunologically distinct, prohibiting effective cross-neutralization across different SARS strains [@doi:10.1101/2020.03.21.990770].
Consequently, earlier proteome-level studies on SARS-CoV can also provide some essential information regarding the new pathogen [@doi:10.1073/pnas.0407992101; @doi:10.1016/j.bbrc.2004.02.074].
Considering the paucity of omics-level big data sets for SARS-CoV-2 up until now, existing data hubs that contain information for other coronaviruses such as UniProt, NCBI Genome Database, The Immune Epitope Database and Analysis Resource (IEDB), and The Virus Pathogen Resource (ViPR) will serve as useful resources for computational and bioinformatics research on SARS-CoV-2.
Using such databases, the systems level reconstruction of the PPI (Protein-Protein Interaction) enabled the generation of hypotheses on the mechanism of action of SARS-CoV-2 and suggested drug targets.
In an initial study [@doi:10.1101/2020.03.22.002386], 26 of the 29 SARS-CoV-2 proteins were cloned and expressed in HEK293T kidney cells, allowing for the identification of 332 high-confidence human proteins that interact with them.
Notably, this study suggested that SARS-CoV-2 interacts with innate immunity pathways.
The ranking of pathogens with respect to their interactome's similarity to SARS-CoV-2 suggested *West Nile Virus*, *Mycobacterium tuberculosis*, and *Human papillomavirus* as the top three hits.
However, given the lung symptoms associated with COVID-19, the *Mycobacterium tuberculosis* host-pathogen interactome could also provide new insights to the mechanism of SARS-CoV-2 infection.
In addition, it was suggested that the envelope protein E could disrupt the host bromodomain-containing proteins, i.e., BRD2 and BRD4, binding to histone.
The Spike protein could likely intervene in the virus fusion through modulating the GOLGA7-ZDHHC5 acyl-transferase complex to increase palmitoylation.

Another study [@doi:10.1101/2020.03.31.019216], used patient-derived peripheral blood mononuclear cells (PBMCs) to identify 251 host proteins targeted by SARS-CoV-2 and the disruption of more than 200 host proteins following the infection.
The network analysis showed in particular that non-structural proteins 9 and 10 (nsp9 and nsp10) interacted with NKRF that usually represses NFKB.
This finding could explain the exacerbation of the immune response that shape the pathology and the high cytokine levels possibly due to the chemotaxis of neutrophils mediated by IL-8 and IL-6.
Finally, it was suggested [@doi:10.1101/2020.04.09.033522] that protein E of both SARS-CoV and SARS-CoV-2 has a conserved Bcl-2 Homology 3 (BH3)-like motif, that could inhibit anti-apoptosis proteins BCL2 and trigger the apoptosis of T cells.
Several known compounds were suggested to disrupt the host-pathogen protein interactome were suggested mostly through the inhibition of host proteins.

### Viral Evolution and Virulence

Like that of SARS-CoV, SARS-CoV-2 entry into host cells is mediated by the interaction between the viral spike glycoprotein (S) and human angiotensin-converting enzyme 2 (ACE2) [@doi:10.1126/science.1116480; @doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2762; @doi:10.1038/s41586-020-2179-y; @doi:10.1101/2020.02.19.956235; @doi:10.1016/j.cell.2020.02.052; @doi:10.1016/j.cell.2020.03.045; @doi:10.1128/jvi.00127-20].
Differences between the two viruses in their interactions between the S protein and hACE2 may also partially account for the increased transmissibility seen in the current COVID-19 pandemic.
Recent studies have reported conflicting binding constants for the S protein-hACE2 interaction, though they agree that SARS-CoV-2 S protein binds with equal if not greater affinity than does SARS-CoV S protein [@doi:10.1016/j.cell.2020.02.058; @doi:10.1101/2020.02.19.956235; @doi:10.1126/science.abb2507].
The C-terminal domain of the SARS-CoV-2 S protein in particular was identified as the key region of the virus that interacts with the human ACE2 (hACE2) receptor, and the crystal structure of the C-terminal domain of SARS-CoV-2 S protein in complex with human ACE2 reveals stronger interaction and higher affinity for receptor binding than SARS-CoV [@doi:10.1016/j.cell.2020.03.045].
Among the 14 key binding residues identified in the SARS-CoV S protein, 8 are conserved in SARS-CoV-2 and the remaining 6 are semi-conservatively substituted, potentially explaining variation in binding affinity [@doi:10.1016/j.cell.2020.02.058; @doi:10.1101/2020.02.19.956235].
Recent crystal structures have shown that the receptor-binding domain (RBD) of SARS-CoV-2 S protein, like that of other coronaviruses, undergoes stochastic hinge-like movement that flips it from a ‚Äúclosed‚Äù conformation, in which key binding residues are hidden at the interface between protomers, to an ‚Äúopen‚Äù one [@doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2507].
Because the RBD plays such a critical role in viral entry, blocking its interaction with ACE2 represents a promising therapeutic approach.
Nevertheless, despite the high structural homology between SARS-CoV-2 RBD and that from SARS-CoV, monoclonal antibodies targeting SARS-CoV-RBD failed to bind SARS-CoV-2-RBD [@doi:10.1126/science.abb2507].
Promisingly though, sera from convalescent SARS patients inhibited SARS-CoV-2 viral entry _in vitro_, albeit with lower efficiency than it inhibited SARS-CoV [@doi:10.1016/j.cell.2020.02.052].

Comparative genomic analysis reveals that several regions of the coronavirus genome are likely critical to virulence.
The S1 domain of the spike protein, which contains the RBM, evolves more rapidly than _S_'s S2 domain [@doi:10.3390/v4061011; @doi:10.1016/j.jmb.2020.04.009].
However, even within the S1 domain, some regions are more conserved than others, with the receptors in S1's N-terminal domain (S1-NTD) evolving more rapidly than those in its C-terminal domain (S1-CTD) [@doi:10.1016/j.jmb.2020.04.009].
Both S1-NTD and S1-CTD are involved in receptor binding and can function as receptor binding domains (RBDs) to bind proteins and sugars [@doi:10.3390/v4061011], but RBDs in the S1-NTD typically bind to sugars, while those in the S1-CTD recognize protein receptors [@doi:10.1146/annurev-virology-110615-042301].
Viral receptors show higher affinity with protein receptors than sugar receptors [@doi:10.1146/annurev-virology-110615-042301], which suggests that positive selection on or relaxed conservation of the S1-NTD preferentially might reduce the risk of a deleterious mutation that would prevent binding.
The SARS-CoV-2 S protein also contains a RRAR furin recognition site at the S1/S2 junction [@doi:10.1016/j.cell.2020.02.058; @doi:10.1126/science.abb2507], setting it apart from bat coronavirus RaTG13, with which it shares 96% genome sequence identity, and SARS-CoV [@doi:10.1038/s41586-020-2012-7].
Such furin cleavage sites are commonly found in highly virulent influenza viruses, and as such may contribute to the heightened pathogenicity of SARS-CoV-2 [@doi:10/bvgh5b; @doi:10.1006/viro.1999.9716].
Effective cell entry is a critical component to pathogenesis and therefore an important process to understand when examining possible therapeutics.

Evolution in SARS-CoV-2 has also been observed over a short timescale.
After zoonotic transfer, SARS-CoV-2 continued evolving in the human population [@doi:10.1186/s12967-020-02344-6].
The SARS-CoV-2 mutation rate is moderate compared to other RNA viruses [@doi:10.1016/j.meegid.2020.104351], which likely restricts the pace of evolution in SARS-CoV-2.
Nevertheless, genomic analyses have yielded statistical evidence of ongoing evolution.
There are two known variants of the spike protein that differ by a single amino acid at position 614 (G614 and D614), and there is evidence that G614 had become more prevalent than D614 by June 2020 [@doi:10.1016/j.cell.2020.06.043].
While there is a hypothesis that this genomic change increased the SARS-CoV-2 infectivity and virulence, this hypothesis has not yet been tested due to a lack of data [@doi:10.1016/j.cell.2020.06.040].
One study [@doi:10.1016/j.meegid.2020.104351] identified 198 recurrent mutations in a dataset of 7666 curated sequences.
This patterns of convergent evolution suggests that some of the sites may indicate that they confer an adaptive advantage.
While it is evident that SARS-CoV-2 exhibits moderate potential for ongoing or future evolution, the relationship between mutations and pathogenicity is not yet known.
Additional data is needed in order to understand patterns of evolutionary change and whether they are likely to affect virulence.
